Goldman Sachs’s Acadia Pharmaceuticals ACAD Stock Holding History

Goldman Sachs’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-89,800	Closed	-$1.92M	–	6412
2025 Q3	$1.92M	Hold	89,800	–	–	﹤0.01%	4525
2025 Q2	$1.94M	Hold	89,800	–	–	﹤0.01%	4208
2025 Q1	$1.49M	Hold	89,800	–	–	﹤0.01%	4382
2024 Q4	$1.65M	Hold	89,800	–	–	﹤0.01%	4455
2024 Q3	$1.38M	Hold	89,800	–	–	﹤0.01%	4418
2024 Q2	$1.46M	Buy	+89,800	New	+$1.45M	﹤0.01%	4173
2020 Q4	–	Sell	-31,900	Closed	-$1.32M	–	5449
2020 Q3	$1.32M	Buy	31,900 +11,900	+60%	+$514K	﹤0.01%	3880
2020 Q2	$969K	Sell	20,000 -54,500	-73%	-$2.62M	﹤0.01%	3975
2020 Q1	$3.15M	Buy	+74,500	New	+$3.07M	﹤0.01%	2992
2019 Q2	–	Sell	-12,700	Closed	-$341K	–	5096
2019 Q1	$341K	Buy	+12,700	New	+$297K	﹤0.01%	4574
2017 Q4	–	Sell	-50,000	Closed	-$1.88M	–	6296
2017 Q3	$1.88M	Buy	+50,000	New	+$1.63M	﹤0.01%	4054
2016 Q4	–	Sell	-100,000	Closed	-$3.18M	–	6865
2016 Q3	$3.18M	Buy	+100,000	New	+$3.39M	﹤0.01%	3424
2016 Q2	–	Sell	-398,000	Closed	-$11.1M	–	7002
2016 Q1	$11.1M	Buy	398,000 +348,000	+696%	+$7.59M	﹤0.01%	2134
2015 Q4	$1.78M	Hold	50,000	–	–	﹤0.01%	3739
2015 Q3	$1.65M	Sell	50,000 -139,700	-74%	-$5.81M	﹤0.01%	3988
2015 Q2	$7.95M	Hold	189,700	–	–	﹤0.01%	2538
2015 Q1	$6.18M	Sell	189,700 -1,221,900	-87%	-$42M	﹤0.01%	2700
2014 Q4	$44.8M	Sell	1,411,600 -1,737,400	-55%	-$49.3M	0.01%	1197
2014 Q3	$78M	Hold	3,149,000	–	–	0.02%	774
2014 Q2	$71.1M	Hold	3,149,000	–	–	0.02%	878
2014 Q1	$76.6M	Sell	3,149,000 -212,900	-6%	-$5.39M	0.03%	759
2013 Q4	$84M	Buy	3,361,900 +25,000	+0.7%	+$590K	0.03%	711
2013 Q3	$91.7M	Hold	3,336,900	–	–	0.03%	635
2013 Q2	$60.6M	Buy	+3,336,900	New	+$46M	0.02%	795

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Goldman Sachs's ACAD Position: Q1 2026 in Review

Goldman Sachs reduced its Acadia Pharmaceuticals (ACAD) stake by 0.78% in Q1 2026, selling an estimated $293K and leaving 1,557,804 shares worth $34.7M. The position accounts for ﹤0.01% of the portfolio, ranked #1897.

Goldman Sachs first reported a position in ACAD in Q2 2013 and has held it in 52 quarters since. The position peaked at $68.6M in Q3 2017. 341 funds tracked by Wall St. Rank hold ACAD as of Q1 2026.

Goldman Sachs held 1,557,804 shares of Acadia Pharmaceuticals worth $34.7M as of Q1 2026.
Goldman Sachs sold 12,247 Acadia Pharmaceuticals shares in Q1 2026, an estimated $293K.
Acadia Pharmaceuticals made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #1897 holding.
Goldman Sachs first reported a position in Acadia Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
Goldman Sachs's Acadia Pharmaceuticals position peaked at $68.6M in Q3 2017.
341 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.